Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants with Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian

This phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating participants with ovarian, fallopian tube, or primary peritoneal cancer that does not respond to treatment. Monoclonal antibodies, such as bevacizumab and anetumab ravtansine, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving bevacizumab and anetumab ravtansine or paclitaxel may work better in treating participants with ovarian, fallopian tube, or primary peritoneal cancer.
Ovarian
II
Crispens, Marta
NCT03587311
VICCGYN18159ET-CT

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: